Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07012135 · ClinicalTrials.gov registry record · NA

Deciphering Preserved Autonomic Function After Multiple Sclerosis

A NA study of Multiple Sclerosis and Autonomic Dysreflexia, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
13
Enrollment target
1
Study location

NCT07012135: Recruiting NA study of Multiple Sclerosis and Autonomic Dysreflexia, sponsored by Mayo Clinic.

NCT07012135 is a NA study of Multiple Sclerosis and Autonomic Dysreflexia that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 13 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07012135, a NA study of Multiple Sclerosis and Autonomic Dysreflexia, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with multiple sclerosis typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with multiple sclerosis and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction with multiple sclerosis will exhibit abnormalities in these precise metrics. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from multiple sclerosis. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after multiple sclerosis and give physicians better tools to manage these secondary autonomic complications.

Primary Outcome

Presence or absence of phase II on Valsalva maneuver testing, which takes approximately 15 seconds to complete. This will be repeated x3.

Interventions

  • DIAGNOSTIC_TEST Tests of sympathetic inhibition
  • DIAGNOSTIC_TEST Tests of sympathetic activation
  • DIAGNOSTIC_TEST Testing of autonomic dysreflexia

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2025-09-17
Est. Completion 2026-12-31
Phase NA
Mayo Clinic

2,844 total trials

What NCT07012135 shows while recruiting

NCT07012135 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Tests of sympathetic inhibition is the first listed.

NCT07012135 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT07012135 about?

NCT07012135 is a clinical study titled "Deciphering Preserved Autonomic Function After Multiple Sclerosis". This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with mult...

What is the current status of trial NCT07012135?

This trial is currently recruiting. It is a NA study. The enrollment target is 13 participants. The study started on 2025-09-17. Estimated completion is 2026-12-31.

What conditions does trial NCT07012135 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Autonomic Dysreflexia, Control Subjects.

What interventions are being tested in trial NCT07012135?

The interventions under investigation include: Tests of sympathetic inhibition (DIAGNOSTIC_TEST), Tests of sympathetic activation (DIAGNOSTIC_TEST), Testing of autonomic dysreflexia (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07012135?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07012135 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07012135's enrollment target sits among peer trials

13 294th of 315 higher than 20 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07012135, the US trial registry maintained by the National Library of Medicine. NCT07012135 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.